oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Molecular tests for the detection of antimicrobial resistant Neisseria gonorrhoeae: when, where, and how to use?
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Department of Laboratory Medicine.
2016 (English)In: Current Opinion in Infectious Diseases, ISSN 0951-7375, E-ISSN 1473-6527, Vol. 29, no 1, 45-51 p.Article, review/survey (Refereed) Published
Resource type
Text
Abstract [en]

Purpose of reviewMolecular methods for the diagnosis of Neisseria gonorrhoeae are replacing bacterial culture in many settings. This review focuses on recent progress in the development of molecular tests to detect resistant N. gonorrhoeae both to enhance surveillance and to guide decisions about individual patient management.Recent findingsAssays to enhance surveillance have been developed to detect determinants of resistance for all antibiotics used as first-line gonorrhoea treatment, or to detect specific superbug' strains, but few have been applied in clinical practice. The most advanced strategy relevant to individual case management is to identify ciprofloxacin-sensitive strains so that unnecessary use of ceftriaxone can be avoided. Cross-reactivity with pharyngeal commensal Neisseria species reduces specificity and is a challenge for many assays.SummaryProgress with laboratory-based molecular tests to detect gonococcal resistance is being made but substantial challenges remain. No laboratory-based assay has been subjected to a field evaluation and no assay so far can be used as a point-of-care test. Given the threat of antimicrobial resistance, now is the time to exploit the molecular technologies used for diagnosis and to invest in the development of molecular gonococcal resistance tests that can be implemented for public health good.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2016. Vol. 29, no 1, 45-51 p.
Keyword [en]
antimicrobial resistance, antimicrobial surveillance, Neisseria gonorrhoeae, point-of-care tests
National Category
Infectious Medicine
Research subject
Infectious Diseases
Identifiers
URN: urn:nbn:se:oru:diva-48757DOI: 10.1097/QCO.0000000000000230ISI: 000369549600007PubMedID: 26658656Scopus ID: 2-s2.0-84952719585OAI: oai:DiVA.org:oru-48757DiVA: diva2:907597
Note

Funding Agency:

Rapid Diagnosis of Resistance in Gonorrhoea (RaDAR-Go) project from SwissTransMed (Platforms for translational research in medicine) 25/2013

Available from: 2016-02-29 Created: 2016-02-29 Last updated: 2016-02-29Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Unemo, Magnus
By organisation
School of Health and Medical Sciences, Örebro University, Sweden
In the same journal
Current Opinion in Infectious Diseases
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 14 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf